A ngiotensin-converting enzyme (ACE) inhibitors reduce morbidity and mortality in patients with chronic heart failure and left ventricular dysfunction as well as in patients who have had a myocardial infarction (MI). [1] [2] [3] [4] ACE inhibitors may exert a cardioprotective effect by decreasing afterload and preload and by inhibiting the cardiac renin-angiotensin system. Orally active, nonpeptide angiotensin II type 1 (AT 1 ) receptor antagonists, such as losartan or candesartan cilexitil, can block this receptor specifically. 5, 6 Raya et al 7 compared the long-term effects of the ACE inhibitor captopril with the direct blockade induced by losartan in a rat model of MI, and both drugs caused similar hemodynamic changes. Several other investigators have made similar comparisons in dog and rat models of MI. 8 -14 In some of these studies, the ACE inhibitor seemed to be superior to the AT 1 receptor antagonist in preventing ventricular remodeling and hypertrophy, 9, 12, 13 whereas in others the two seemed similar. 7, 8, 10, 11, 13, 14 Recently, investigators in the Evaluation of Losartan in the Elderly (ELITE) study found that losartan was, contrary to expectations, associated with lower mortality than captopril in patients with heart failure. 15 On the other hand, in the RESOLVD study, a trial comparing candesartan with enalapril in patients with heart failure, no difference in effects on clinical events or death between the two drugs was shown. 16 A comparison of the effects of AT 1 receptor antagonists and ACE inhibitors on heart failure has not been performed.
Two-dimensional echocardiography allows visualization of the entire heart through multiple tomographic planes in real time and has become the noninvasive method of choice for evaluating chamber size and function. Pulsed-wave Doppler recordings of atrioventricular valve flow provide valuable information about diastolic filling of the heart, 17 and transthoracic Doppler echocardiography has become a powerful noninvasive method that has been used to provide information about systolic and diastolic function in small-animal studies. 18, 19 The present study was undertaken to compare the effects of an AT 1 receptor antagonist (candesartan cilexitil) and an ACE inhibitor (cilazapril) on cardiac dysfunction in rats after MI. For this purpose, we measured cardiac function by using Doppler echocardiography and ventricular mRNA expression of several genes associated with cardiac hypertrophy.
Methods

Experimental Protocol
All procedures were in accordance with institutional guidelines for animal research. Male Wistar rats weighing 290 to 310 g were purchased from Clea Japan, Inc (Osaka, Japan). MI was produced by ligation of the left anterior descending coronary artery as previously described. 20, 21 The same surgical procedures were performed on a control group of rats (1 week, nϭ8; 4 weeks, nϭ8) except that the suture around the coronary artery was not tied. Rats that survived 24 hours after surgery were randomly separated into treated and untreated groups (MI groups: 1 week, nϭ9; 4 weeks, nϭ8). Treated rats were orally administered candesartan cilexitil (candesartan) (1 or 10 mg/kg) or cilazapril (1 or 10 mg/kg) in a volume of 2 mL/kg by gastric gavage once per day for 1 or 4 weeks after MI (candesartan, 1 mg/kg: 1 week, nϭ10; 4 weeks, nϭ9; candesartan, 10 mg/kg: 1 week, nϭ11; 4 weeks, nϭ10; cilazapril, 1 mg/kg: 1 week, nϭ10; 4 weeks, nϭ10; cilazapril, 10 mg/kg: 1 week, nϭ9; 4 weeks, nϭ10). Untreated rats were administered vehicle (5% gum arabic solution) in the same manner (1 week, nϭ9; 4 weeks, nϭ8).
Doppler Echocardiographic and Hemodynamic Studies
Transthoracic Doppler echocardiography was performed on each rat by modifying the method described by Litwin et al. 18 End-diastolic area was defined as the largest left ventricular area and end-systolic as the smallest; calculations of ventricular chamber size were previously published by Scherrer-Crosbie et al. 22 Ejection fraction was measured by modifying Simpson's method, which uses 2-and 4-chamber views (Figure 1) . 23 The hemodynamic studies are described in detail elsewhere. 24 Myocardial infarct size was measured as previously described. 21 Rats with an infarct size of Ͻ20% were excluded from analysis. After determination of infarct size, the left ventricle was divided into 3 parts, the infarcted region, myocardium around the infarcted zone in the free left ventricle (adjacent noninfarcted myocardium), and septal myocardium (remote noninfarcted myocardium). The infarct induced by ligation of the descending coronary artery in the rat occurred in the free wall of the left ventricle.
Northern Blot Hybridization
The method of Northern blot hybridization used is described in detail elsewhere. 25 
Statistics
Results are meanϮSE. Statistical significance was determined using ANOVA and Duncan's multiple range test. Differences were considered significant at PϽ0.05.
Results
Effects of Candesartan and Cilazapril on Hemodynamics and Heart Weight
As shown in Table 1 , both candesartan and cilazapril significantly lowered mean blood pressure and left ventricular systolic pressure (LVSP) in rats with MI. The 10-mg/kg per day doses of candesartan and cilazapril decreased mean blood pressure and LVSP more than the 1-mg/kg per day doses. However, there was no significant difference in hypotensive effects among the 4 groups. Left ventricular end-diastolic pressure (LVEDP) and central venous pressure (CVP) were significantly higher in rats with MI at 1 and 4 weeks than in controls. In treated rats, LVEDP and CVP decreased to a similar extent. Right ventricular weight (0.78Ϯ0.03 g/kg, PϽ0.01) was significantly higher in rats with MI than in controls (0.56Ϯ0.03 g/kg) at 4 weeks. Left ventricular weight was lower in rats with MI than in controls at 1 week and was the same in both controls and rats with MI at 4 weeks, which means that scar formation in the infarcted region decreased left ventricular weight at 1 week and canceled the weight increased by cardiac hypertrophy of the noninfarcted regions at 4 weeks (1 week: control, 2.12Ϯ0.05 g/kg; MI, 1.99Ϯ0.04 g/kg; PϽ0.05; 4 weeks: control, 2.14Ϯ0.05 g/kg; MI, 2.15Ϯ0.07 g/kg; NS). Candesartan and cilazapril significantly prevented an increase in heart weight at 4 weeks. There was no significant difference in heart weights among the 4 treated groups.
Doppler Echocardiographic Assessment of Left Ventricular Geometry and Function
Left ventricular cavity size significantly increased in rats with MI at 1 and 4 weeks (1 week: control, 6.0Ϯ0.6 mm; MI, 8.2Ϯ0.4 mm; PϽ0.01; 4 weeks: control, 6.7Ϯ0.3 mm; MI, 10.3Ϯ0.7 mm; PϽ0.01) (see Table 2 ). Rats with MI had significant systolic dysfunction, as evidenced by decreased fractional shortening (control, 38Ϯ4%; MI, 20Ϯ2%; PϽ0.05) at 1 week. Left ventricular posterior wall thickness was not changed at 1 week and had decreased at 4 weeks. Candesartan and cilazapril significantly prevented left ventricular cavity dilatation and decreases in ejection fraction and fractional shortening at 4 weeks (Figure 2A ). There was no significant difference in improvement of systolic function among the 4 treated groups. Examples of pulsed-wave Doppler recordings of mitral inflow from control rats and from untreated, candesartantreated (1 mg/kg per day), and cilazapril-treated (1 mg/kg per day) rats with MI at 1 week are shown in Figure 2B . At 1 week, peak early diastolic filling (E-wave) velocity increased (control, 56Ϯ4 cm/s; MI, 110Ϯ10 cm/s; PϽ0.01) and deceleration of the E wave became more rapid (control, 16.0Ϯ2.3 m/s 2 ; MI, 26.3Ϯ2.6 m/s 2 ; PϽ0.01). Atrial filling (A-wave) velocity decreased (control, 33Ϯ4 cm/s; MI, 13Ϯ2 cm/s; PϽ0.01), resulting in a marked increase in the ratio of E-wave to A-wave velocity (E/A) (control, 1.9Ϯ0.2; MI, 9.2Ϯ0.6; PϽ0.01). Candesartan and cilazapril significantly prevented worsening of diastolic dysfunction, as evidenced by E/A and the deceleration rate of the E wave at 1 and 4 weeks. There was no significant difference in improvement of diastolic function among the 4 treated groups.
Gene Expression of Contractile Proteins, Atrial Natriuretic Peptide, and Collagens
The results of cardiac gene expression at 1 and 4 weeks are shown in Figure 3 and Tables 3 and 4 . At 1 week after MI, ␤-myosin heavy chain (␤-MHC), ␣-skeletal actin, atrial natriuretic peptide (ANP), and collagen I and III mRNA expression increased 4.5-, 3.1-, 9.4-, 14.3-, and 8.4-fold (PϽ0.01), respectively, in the adjacent noninfarcted myocardium. Gene expression increased significantly in the remote noninfarcted left ventricle (septum) and right ventricle. These genes were predominantly expressed in the adjacent noninfarcted myocardium rather than the remote noninfarcted left ventricle and right ventricle. At 1 week, candesartan and cilazapril significantly prevented mRNA expression of ␤-MHC, ␣-skeletal actin, and ANP in the adjacent and remote noninfarcted left ventricles and right ventricle but did not affect mRNA expression of collagens I and III in any region. At 4 weeks, ␤-MHC, ␣-skeletal actin, ANP, and collagen I and III mRNA expression remained increased. Both candesartan and cilazapril prevented these increases significantly in all regions. There was no significant difference in prevention of cardiac gene expression among the 4 treated groups. Figure 4 shows hearts from control rats and from untreated, candesartan-treated (10 mg/kg per day), and cilazapril-treated (10 mg/kg per day) rats at 12 weeks after MI. Both the AT 1 antagonist and ACE inhibitor apparently prevented enlargement of a typical remodeled heart at 12 weeks after MI.
Discussion
As expected, our study showed that treatment with candesartan or cilazapril attenuates left ventricular dilatation and cardiac hypertrophy in the noninfarcted region and improves ejection fraction (measured by the modified Simpson's method), fractional shortening, and left ventricular wall thickening at 4 weeks after MI. A variety of ways to calculate volumes have been proposed. Measuring ejection fraction with the Figure 2 . A, M-mode echocardiograms from control rats, and untreated, candesartan-treated (1 mg/kg per day) (AT1), and cilazapril-treated (1 mg/kg per day) (ACEI) rats with MI at 4 weeks. Note left ventricular cavity dilatation, thinning and akinesis of the anterior wall, and hypokinesis of the posterior wall motion in the rats with MI. Candesartan and cilazapril equally prevented left ventricular dilatation and improved posterior wall motion. AW indicates anterior wall; and PW, posterior wall. B, Pulsed-wave Doppler spectra of mitral inflow from control rats, and candesartan-treated (1 mg/kg per day) (AT1) and cilazapriltreated (1 mg/kg per day) (ACEI) rats with MI at 1 week. The mitral inflow pattern of rats with MI shows increased peak E-wave velocity, rapid deceleration of the E wave, and decreased peak A-wave velocity compared with controls. Candesartan and cilazapril visually changed a relatively normal transmitral flow pattern in rats with MI to the same extent. modified Simpson's method is the most reliable way to assess systolic function using echocardiographic parameters because it minimizes the effect of geometric shape for calculating volumes. Left ventricular weight in the untreated infarct group was the same as in the control group at 4 weeks despite the presence of infarcts and considerable loss of myocardium (which was replaced by a thin wall of scar tissue), which suggests that reactive hypertrophy of the noninfarcted left ventricle occurred. Consequently, the reduced left ventricular weights of the candesartan-and cilazapril-treated groups indicate that reactive hypertrophy was prevented. Relatively little improvement of systolic function was induced by candesartan or cilazapril, but this increase coincided with a decrease in LVEDP, suggesting that the pumping ability of the left ventricle was significantly improved.
Doppler echocardiography is currently the primary technique for evaluating left ventricular diastolic function. 17 Increased E-wave velocity, decreased peak A-wave velocity (or absent A wave), and rapid E-wave deceleration were observed in our rats, and these flow patterns were similar to transmitral flow profiles observed in patients with heart failure with restrictive patterns. Both candesartan and cilazapril decreased the E/A ratio and E-wave deceleration rate at 1 and 4 weeks. Long-term ACE inhibitor therapy could prevent changes in left ventricular diastolic properties in patients with depressed ejection fraction. 26 We recently reported that candesartan improved the diastolic filling pattern in rats with MI. 27 Our data showed that candesartan and cilazapril prevented abnormal diastolic filling before systolic dysfunction after MI. This effect of ACE inhibitors has been already reported. 28 Improvement of diastolic filling is caused by preload, afterload reduction, improvement in left ventricular relaxation, or decrease in passive elastic properties. Our data do not directly answer the difficult question of whether the changes in left ventricle filling are due to changes in myocardial properties, changes in left ventricle loading conditions, or both. However, when viewed in the context of previous studies using isolated muscle preparations from the same model of heart failure, 29, 30 the improvements in diastolic filling that accompany inhibition of the renin-angiotensin system result from a combination of effects on left ventricular preload and afterload as well as left ventricular chamber properties.
During the early phase of MI, the heart attempts to provide hemodynamic compensation at the expense of ventricular dilatation (Frank-Starling law). 31 Chronic, continued hemo- dynamic stress leads to pathological hypertrophy and progressive dilatation. We have noted that MI occurs in the free wall in rats; therefore, the marginal zone of the infarcted region (myocardium adjacent to infarct region) is located in the left ventricular free wall. Thus, we must examine the left ventricular free wall and septum to analyze the properties of the whole noninfarcted left ventricle. Left ventricular remodeling after MI is known to be accompanied by severe hypertrophy of the myocyte and dysfunction of regions adjacent to the infarct. We previously reported that fetal genes (␤-MHC, ␣-skeletal actin, and ANP) are predominantly expressed in adjacent noninfarcted myocardium. However, the pattern of fetal gene expression did not differ between adjacent and remote noninfarcted myocardium. 24 In the present study, candesartan and cilazapril equally prevented fetal gene expression at 1 and 4 weeks and collagen gene expression at 4 weeks, indicating that both the AT 1 receptor antagonist and the ACE inhibitor attenuate remodeling of the myocyte and nonmyocyte compartments to a similar extent after MI. Although candesartan and cilazapril inhibited increased mRNA expression of collagens I and III at 4 weeks, neither drug did so at 1 week. AT 1 receptor antagonists and ACE inhibitors are reported to suppress interstitial fibrosis in noninfarcted myocardium. 11 We believe the reason is that the half-life of collagen is 80 to 120 days, 32 which would make it difficult to detect a change in gene expression after 1 week of treatment.
McDonald et al 9 reported that ACE inhibitors, but not AT 1 receptor antagonists, attenuate left ventricular remodeling in dogs after transmyocardial direct shock. Moreover, they showed a possible role of the bradykinin B2-receptor antag- Figure 4 . Hearts in control rats, untreated rats with MI, and candesartan-treated (10 mg/kg per day) and cilazapril-treated (10 mg/kg per day) rats at 12 weeks after MI. Candesartan and cilazapril apparently prevented enlargement of the remodeled heart. MI indicates rats with MI that were untreated; AT1, rats treated with candesartan; and ACEI, rats treated with cilazapril. onist HOE 140 in the antiremodeling effect of ACE inhibitors in this model. 33 Because ACE inhibitors block degradation of bradykinin and because candesartan and cilazapril have the same cardioprotective effect, we may interpret these data to indicate that the cardioprotective effect of ACE inhibitors is due to blockade of the conversion of angiotensin I to angiotensin II, not inhibition of kinin hydrolysis. However, the effect of the AT 1 receptor antagonist may not be entirely due to blockade of the AT 1 receptor. Angiotensin receptors comprise 2 major subtypes, AT 1 and AT 2 . 34 When the AT 1 receptor is blocked, plasma renin and angiotensin increase; angiotensin may act on AT 2 receptors, which could have an antitrophic effect either directly or via the release of autocoids, such as kinins 35, 36 and nitric oxide, 37, 38 and consequently may contribute to the therapeutic effect of AT 1 receptor antagonist by a mechanism similar to that of kinins. Liu et al 8 reported that the effect of the ACE inhibitor is mediated in part by kinins, whereas that of the AT 1 receptor antagonist is triggered by activation of the AT 2 receptor and is also mediated in part by kinins. Nunez et al 39 showed that combination of an ACE inhibitor and AT 1 receptor antagonist improved hemodynamics in association with reduced left ventricular mass in spontaneously hypertensive rats. However, additional studies are needed to verify that the release of autocoids by AT 1 receptor antagonists has the same beneficial effects on systolic and diastolic function as those induced by inhibition of bradykinin degradation by an ACE inhibitor. In summary, candesartan and cilazapril had equally beneficial effects on cardiac function, as assessed by Doppler echocardiography and cardiac gene expression, after MI.
